Search results for: OHE Consulting
Filter search results
A Note on the Relationship Between Age and Health-related Quality of Life Assessment
12 December 2018
A new OHE-authored paper on the relationship between age and health-related quality of life has been published in Quality of Life Research. A new article entitled A note on the…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…see our earlier blog post. For information on other recent OHE activities in this areas, see our December blog post. For additional information, please contact Nancy Devlin at OHE. …
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…Association (DIA), OHE’s Jorge Mestre-Ferrandiz presented the results of OHE research into R&D discontinuations. The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of…
Using Competition with Care: Comment on the Revised Regulations for the NHS
19 March 2013
OHE’s Jon Sussex has studied and written extensively on competition in the NHS. He was a member of the OHE Commission on Competition in the NHS and rapporteur of its…
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
…19th OHE annual lecture. London: Office of Health Economics. The 2013 OHE Annual Lecture, scheduled for 16 July, will address quality in the NHS and be given by Professor Alan…
Special Issue of EJHE Examines Progress on Refinement of the EQ-5D
13 August 2013
…co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…(OHE) and its collaborators, medicines for rare disease may be effectively valued using an innovative approach — multi-criteria decision analysis (MCDA) — that can include all relevant stakeholders, including patients’…